Monitor the January 2027 Varseta-M Phase 1 data update for dose selection and registrational strategy clarity; the cash runway into H2 2028 provides a long development horizon but the lack of near-term revenue catalysts keeps the stock dependent on pipeline milestones.
Drugs in focus
CTMX drug pipeline →Varseta-M
▲ Bullish Named in this press release- Impact
- Phase
- Phase 1
- Time to market
- If the Phase 1 update supports the registrational study planned for H1 2027, a potential FDA approval would likely be several years away, assuming successful pivotal trial execution. The Fast Track designation could accelerate timelines, but the drug is still in Phase 1 development.
- Next catalyst
- None dated
What to watchThe next major catalyst is the Phase 1 monotherapy data update in mCRC expected in January 2027 (roughly 2 months away). Positive data could support the planned registrational study start in H1 2027 and drive significant upside given the stock trades near cash value. Disappointing efficacy or safety signals could delay the pivotal program and pressure the stock toward its 52-week low of $2.11.
Price Chart
Executive Summary
CytomX reported Q3 2026 revenue of $1.7M, down from $6.0M a year ago due to the completion of the Astellas collaboration, and a net loss of $20.0M ($0.09 per share) versus a $14.2M loss in Q3 2025. The company highlighted FDA Fast Track designation for Varseta-M in colorectal cancer and plans for a Phase 1 data update in January 2027, but the financial results reflect a pre-revenue clinical-stage biotech burning cash with no near-term product revenue.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $1.7M vs $6.0M in Q3 2025, down 72% due to completion of Astellas collaboration performance obligation
- Net loss $20.0M ($0.09 per share) vs net loss $14.2M ($0.09 per share) in Q3 2025
- Cash, cash equivalents and investments $348.0M at end of Q3 2026, up from $330.3M at Q2 2026; cash runway into H2 2028
- R&D expenses $16.5M vs $15.3M in Q3 2025; G&A expenses $8.7M vs $6.4M in Q3 2025
- FDA Fast Track designation granted for Varseta-M in relapsed/refractory metastatic colorectal cancer
- Phase 1 monotherapy data update for Varseta-M in mCRC expected January 2027; potential registrational study initiation in H1 2027
- Phase 1/2 combination study of Varseta-M with chemotherapy in 2L mCRC planned by end of 2026
- CX-801 Phase 1 in advanced melanoma continues; initial combo data with KEYTRUDA expected H1 2027
Financial Impact
Revenue decline of $4.3M YoY; net loss increased by $5.8M; cash position grew by $17.7M QoQ
Risk Factors
- Revenue decline reflects completion of Astellas collaboration; no new partnership revenue visible
- Operating losses are widening as R&D and G&A costs increase
- Varseta-M is still in early Phase 1; clinical failure or delay would remove the primary value driver
- Dilution risk from ongoing share count growth (219M shares vs 165M a year ago)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3397134 |
Track record
10 reports on CTMX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13G Neutral 2/10 Entry $1.98 Now $1.99 +0.25% settles Feb 8
- Nov 5, 202611d ago Press Release Bearish 5/10 Viewing No price data
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.19 Now $1.99 −9.36% settles Feb 4
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $2.36 Now $1.99 −15.89% settles Jan 26
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $2.94 Now $1.99 −32.48% settles Dec 16
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $3.15 to $2.77 Now $1.99 −36.98% ▼ −12.22% −15.47% vs SPY
- Mar 17, 202634w ago Press Release Neutral 6/10 Entry $4.40 to $2.98 Now $1.99 −54.89% ▼ −32.27% −43.80% vs SPY
- Mar 16, 202635w ago Press Release Bearish 7/10 Entry $5.45 to $2.98 Now $1.99 +63.58% ▲ +45.32% +55.18% vs SPY
- Mar 16, 202635w ago Press Release Mixed 6/10 Entry $6.75 to $2.94 Now $1.99 −70.59% ▼ −56.44% −66.93% vs SPY
- Mar 4, 202636w ago Press Release Neutral 3/10 Entry $5.07 to $3.71 Now $1.99 −60.85% ▼ −26.82% −36.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers